Corporate venturing unit Shire Strategic Investment has led the latest investment in biotech company Promedior. They close their D round at $24.5m

 Promedior, a US-based biotech company developing therapeutics for the treatment of fibrosis, has closed its Series D round at $24.5m, having just added a $3m investment from corporate venture capital firm Shire Strategic Investment Group. Promedior received $21.5m in July of this year led by Fibrotic Ventures. Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.